Nantahala Capital Management LLC Acquires Shares of 6,976,810 Savara Inc. $SVRA

Nantahala Capital Management LLC acquired a new stake in Savara Inc. (NASDAQ:SVRA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 6,976,810 shares of the company’s stock, valued at approximately $42,977,150. Savara accounts for approximately 0.0% of Nantahala Capital Management LLC’s holdings, making the stock its 8th largest position.

A number of other hedge funds have also added to or reduced their stakes in SVRA. Prudential Financial Inc. bought a new stake in shares of Savara during the second quarter valued at approximately $30,000. BNP Paribas Financial Markets boosted its holdings in shares of Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after purchasing an additional 4,626 shares during the period. Brevan Howard Capital Management LP bought a new position in Savara in the second quarter worth approximately $33,000. Russell Investments Group Ltd. grew its stake in Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after purchasing an additional 9,463 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new position in Savara in the third quarter worth approximately $44,000. 87.93% of the stock is currently owned by institutional investors.

Savara Trading Down 4.2%

NASDAQ SVRA opened at $5.26 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.13 and a current ratio of 10.13. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -9.07 and a beta of 0.29. The company’s 50-day simple moving average is $5.70 and its two-hundred day simple moving average is $5.48. Savara Inc. has a one year low of $3.19 and a one year high of $7.01.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Equities analysts forecast that Savara Inc. will post -0.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on SVRA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.14.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.